LPTX Utang jangka cendhak perusahaan Leap Therapeutics

Leap Therapeutics, Inc. (LPTX) focuses on bringing the DKN-01 antibody to market through alliances with pharmaceutical giants. The company's revenues will be based on the commercial implementation of divacilibumab for the treatment of solid tumors. High demand in the targeted therapy segment opens broad licensing opportunities. The company's current liabilities demonstrate borrowing dynamics, while the 0.00 indicator confirms the current level of debt load.

Short-term debt measures a company's obligations with a maturity horizon of up to one year, allowing an investor to assess liquidity risk and the probability of a cash shortfall via a short-term debt chart. Monitoring this metric is critical for Leap Therapeutics, Inc. (LPTX), as stable financing ensures the development of proprietary protocols and the protection of intellectual property during the creation of DKN-01 antibodies in the immuno-oncology sector.